Do analysts prefer XAGE or PTHL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longevity Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, XAGE or PTHL?

Pheton has lower revenue, but higher earnings than Longevity Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Longevity Health $1.05M 0.44 -$10.37M -$4.29 N/A Pheton $305.22K 6.58 -$660K N/A N/A

Is XAGE or PTHL more profitable?

Pheton has a net margin of 0.00% compared to Longevity Health's net margin of -682.67%. Company Net Margins Return on Equity Return on Assets Longevity Health -682.67% N/A -261.90% Pheton N/A N/A N/A

Do analysts recommend XAGE or VBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longevity Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to XAGE or VBIO?

In the previous week, Valion Bio, Inc. Common Stock had 2 more articles in the media than Longevity Health. MarketBeat recorded 3 mentions for Valion Bio, Inc. Common Stock and 1 mentions for Longevity Health. Longevity Health's average media sentiment score of 0.75 beat Valion Bio, Inc. Common Stock's score of 0.30 indicating that Longevity Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Longevity Health 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Valion Bio, Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate XAGE or RBOT?

Vicarious Surgical has a consensus target price of $7.00, suggesting a potential upside of 4,017.65%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, analysts clearly believe Vicarious Surgical is more favorable than Longevity Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longevity Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Vicarious Surgical 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media favor XAGE or RBOT?

In the previous week, Longevity Health and Longevity Health both had 1 articles in the media. Longevity Health's average media sentiment score of 0.75 beat Vicarious Surgical's score of 0.00 indicating that Longevity Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Longevity Health 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vicarious Surgical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend XAGE or LYRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longevity Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media refer more to XAGE or LYRA?

In the previous week, Longevity Health and Longevity Health both had 1 articles in the media. Longevity Health's average media sentiment score of 0.75 beat Lyra Therapeutics' score of -0.71 indicating that Longevity Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Longevity Health 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lyra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts recommend XAGE or SSKN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longevity Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Strata Skin Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Longevity Health (XAGE) Competitors

$0.26 0.00 (0.00%)

As of 11:31 AM Eastern

Compare

XAGE vs. PTHL, VBIO, RBOT, LYRA, and SSKN

Should you buy Longevity Health stock or one of its competitors? MarketBeat compares Longevity Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Longevity Health include Pheton (PTHL), Valion Bio, Inc. Common Stock (VBIO), Vicarious Surgical (RBOT), Lyra Therapeutics (LYRA), and Strata Skin Sciences (SSKN). These companies are all part of the "medical equipment" industry.

How does Longevity Health compare to Pheton?

Longevity Health (NASDAQ:XAGE) and Pheton (NASDAQ:PTHL) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Pheton has lower revenue, but higher earnings than Longevity Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longevity Health	$1.05M	0.44	-$10.37M	-$4.29	N/A
Pheton	$305.22K	6.58	-$660K	N/A	N/A

24.2% of Longevity Health shares are held by institutional investors. 29.0% of Longevity Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Pheton has a net margin of 0.00% compared to Longevity Health's net margin of -682.67%.

Company	Net Margins	Return on Equity	Return on Assets
Longevity Health	-682.67%	N/A	-261.90%
Pheton	N/A	N/A	N/A

In the previous week, Longevity Health had 1 more articles in the media than Pheton. MarketBeat recorded 1 mentions for Longevity Health and 0 mentions for Pheton. Longevity Health's average media sentiment score of 0.75 beat Pheton's score of 0.00 indicating that Longevity Health is being referred to more favorably in the media.

Company	Overall Sentiment
Longevity Health	Positive
Pheton	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longevity Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Longevity Health has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Pheton has a beta of 5.4, indicating that its stock price is 440% more volatile than the broader market.

Summary

Pheton beats Longevity Health on 6 of the 11 factors compared between the two stocks.

How does Longevity Health compare to Valion Bio, Inc. Common Stock?

Longevity Health (NASDAQ:XAGE) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

In the previous week, Valion Bio, Inc. Common Stock had 2 more articles in the media than Longevity Health. MarketBeat recorded 3 mentions for Valion Bio, Inc. Common Stock and 1 mentions for Longevity Health. Longevity Health's average media sentiment score of 0.75 beat Valion Bio, Inc. Common Stock's score of 0.30 indicating that Longevity Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Longevity Health	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Valion Bio, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to Longevity Health's net margin of -682.67%. Longevity Health's return on equity of 0.00% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longevity Health	-682.67%	N/A	-261.90%
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%

24.2% of Longevity Health shares are held by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 29.0% of Longevity Health shares are held by insiders. Comparatively, 2.2% of Valion Bio, Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valion Bio, Inc. Common Stock has lower revenue, but higher earnings than Longevity Health. Valion Bio, Inc. Common Stock is trading at a lower price-to-earnings ratio than Longevity Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longevity Health	$1.05M	0.44	-$10.37M	-$4.29	N/A
Valion Bio, Inc. Common Stock	$780K	2.06	-$8.88M	-$6.68	N/A

Longevity Health has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longevity Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Longevity Health and Valion Bio, Inc. Common Stock tied by winning 7 of the 14 factors compared between the two stocks.

How does Longevity Health compare to Vicarious Surgical?

Longevity Health (NASDAQ:XAGE) and Vicarious Surgical (NYSE:RBOT) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

24.2% of Longevity Health shares are owned by institutional investors. Comparatively, 47.3% of Vicarious Surgical shares are owned by institutional investors. 29.0% of Longevity Health shares are owned by company insiders. Comparatively, 11.1% of Vicarious Surgical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Vicarious Surgical has a consensus target price of $7.00, suggesting a potential upside of 4,017.65%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, analysts clearly believe Vicarious Surgical is more favorable than Longevity Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longevity Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Longevity Health has higher revenue and earnings than Vicarious Surgical. Longevity Health is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longevity Health	$1.05M	0.44	-$10.37M	-$4.29	N/A
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A

Longevity Health has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Vicarious Surgical has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market.

In the previous week, Longevity Health and Longevity Health both had 1 articles in the media. Longevity Health's average media sentiment score of 0.75 beat Vicarious Surgical's score of 0.00 indicating that Longevity Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Longevity Health	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vicarious Surgical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vicarious Surgical has a net margin of 0.00% compared to Longevity Health's net margin of -682.67%. Longevity Health's return on equity of 0.00% beat Vicarious Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longevity Health	-682.67%	N/A	-261.90%
Vicarious Surgical	N/A	-184.13%	-112.50%

Summary

Vicarious Surgical beats Longevity Health on 7 of the 13 factors compared between the two stocks.

How does Longevity Health compare to Lyra Therapeutics?

Longevity Health (NASDAQ:XAGE) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

In the previous week, Longevity Health and Longevity Health both had 1 articles in the media. Longevity Health's average media sentiment score of 0.75 beat Lyra Therapeutics' score of -0.71 indicating that Longevity Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Longevity Health	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lyra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Longevity Health has a net margin of -682.67% compared to Lyra Therapeutics' net margin of -5,491.17%. Longevity Health's return on equity of 0.00% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longevity Health	-682.67%	N/A	-261.90%
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%

Longevity Health has higher revenue and earnings than Lyra Therapeutics. Longevity Health is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longevity Health	$1.05M	0.44	-$10.37M	-$4.29	N/A
Lyra Therapeutics	$600K	1.78	-$93.43M	-$19.15	N/A

24.2% of Longevity Health shares are held by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are held by institutional investors. 29.0% of Longevity Health shares are held by company insiders. Comparatively, 3.3% of Lyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longevity Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Longevity Health has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Lyra Therapeutics has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

Summary

Longevity Health beats Lyra Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Longevity Health compare to Strata Skin Sciences?

Longevity Health (NASDAQ:XAGE) and Strata Skin Sciences (NASDAQ:SSKN) are both small-cap medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

Longevity Health has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Strata Skin Sciences has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market.

Strata Skin Sciences has higher revenue and earnings than Longevity Health. Strata Skin Sciences is trading at a lower price-to-earnings ratio than Longevity Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longevity Health	$1.05M	0.44	-$10.37M	-$4.29	N/A
Strata Skin Sciences	$30.98M	0.02	-$10.09M	-$1.41	N/A

24.2% of Longevity Health shares are held by institutional investors. Comparatively, 32.4% of Strata Skin Sciences shares are held by institutional investors. 29.0% of Longevity Health shares are held by insiders. Comparatively, 40.9% of Strata Skin Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Longevity Health had 1 more articles in the media than Strata Skin Sciences. MarketBeat recorded 1 mentions for Longevity Health and 0 mentions for Strata Skin Sciences. Longevity Health's average media sentiment score of 0.75 beat Strata Skin Sciences' score of 0.00 indicating that Longevity Health is being referred to more favorably in the media.

Company	Overall Sentiment
Longevity Health	Positive
Strata Skin Sciences	Neutral

Strata Skin Sciences has a net margin of -35.64% compared to Longevity Health's net margin of -682.67%. Longevity Health's return on equity of 0.00% beat Strata Skin Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longevity Health	-682.67%	N/A	-261.90%
Strata Skin Sciences	-35.64%	-476.73%	-33.49%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longevity Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Strata Skin Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Strata Skin Sciences beats Longevity Health on 9 of the 14 factors compared between the two stocks.

Get Longevity Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XAGE vs. The Competition

Export

Metric	Longevity Health	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$463K	$3.10B	$4.44B	$12.58B
Dividend Yield	N/A	N/A	13.33%	6.16%
P/E Ratio	-0.06	19.05	23.49	25.45
Price / Sales	0.44	350.70	174.51	103.18
Price / Cash	N/A	8.66	36.86	58.59
Price / Book	-0.04	5.89	15.15	6.65
Net Income	-$10.37M	$7.39M	$114.87M	$336.83M
7 Day Performance	-14.78%	2.15%	2.14%	3.00%
1 Month Performance	-13.33%	-5.84%	-2.15%	0.56%
1 Year Performance	-89.39%	-33.61%	12.37%	30.42%

Longevity Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XAGE Longevity Health	N/A	$0.26 flat	N/A	-89.7%	$463K	$1.05M	N/A	14
PTHL Pheton	N/A	$0.32 +2.2%	N/A	-98.3%	$2.11M	$305.22K	N/A	11
VBIO Valion Bio, Inc. Common Stock	1.1282 of 5 stars	$0.52 -1.6%	N/A	-87.5%	$1.68M	N/A	N/A	10	Short Interest Increase Gap Up
RBOT Vicarious Surgical	1.7626 of 5 stars	$0.21 +10.1%	$7.00 +3,247.7%	-98.1%	$1.49M	N/A	N/A	210
LYRA Lyra Therapeutics	0.234 of 5 stars	$0.56 flat	N/A	-92.2%	$994K	$600K	N/A	50	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XAGE) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Longevity Health (XAGE) Competitors

XAGE vs. PTHL, VBIO, RBOT, LYRA, and SSKN

How does Longevity Health compare to Pheton?

Summary

How does Longevity Health compare to Valion Bio, Inc. Common Stock?

Summary

How does Longevity Health compare to Vicarious Surgical?

Summary

How does Longevity Health compare to Lyra Therapeutics?

Summary

How does Longevity Health compare to Strata Skin Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XAGE vs. The Competition

Longevity Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Longevity Health (XAGE) Competitors

XAGE vs. PTHL, VBIO, RBOT, LYRA, and SSKN

How does Longevity Health compare to Pheton?

Which has better earnings and valuation, XAGE or PTHL?

Do insiders and institutionals believe in XAGE or PTHL?

Is XAGE or PTHL more profitable?

Does the media refer more to XAGE or PTHL?

Do analysts prefer XAGE or PTHL?

Which has more risk & volatility, XAGE or PTHL?

Summary

How does Longevity Health compare to Valion Bio, Inc. Common Stock?

Does the media refer more to XAGE or VBIO?

Is XAGE or VBIO more profitable?

Do insiders & institutionals have more ownership in XAGE or VBIO?

Which has higher earnings & valuation, XAGE or VBIO?

Which has more risk & volatility, XAGE or VBIO?

Do analysts recommend XAGE or VBIO?

Summary

How does Longevity Health compare to Vicarious Surgical?

Do insiders and institutionals have more ownership in XAGE or RBOT?

Do analysts rate XAGE or RBOT?

Which has higher earnings and valuation, XAGE or RBOT?

Which has more risk & volatility, XAGE or RBOT?

Does the media favor XAGE or RBOT?

Is XAGE or RBOT more profitable?

Summary

How does Longevity Health compare to Lyra Therapeutics?

Does the media refer more to XAGE or LYRA?

Is XAGE or LYRA more profitable?

Which has stronger earnings and valuation, XAGE or LYRA?

Do insiders & institutionals have more ownership in XAGE or LYRA?

Do analysts recommend XAGE or LYRA?

Which has more volatility and risk, XAGE or LYRA?

Summary

How does Longevity Health compare to Strata Skin Sciences?

Which has more volatility & risk, XAGE or SSKN?

Which has better valuation and earnings, XAGE or SSKN?

Do institutionals and insiders have more ownership in XAGE or SSKN?

Does the media refer more to XAGE or SSKN?

Is XAGE or SSKN more profitable?

Do analysts recommend XAGE or SSKN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XAGE vs. The Competition

Longevity Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools